


REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,

  
\_\_\_\_\_  
Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1

2200 Clarendon Boulevard, Suite 1400

Arlington, VA 22201

Direct Dial: 703-812-5311

Facsimile: 703-243-6410

Email: zelano@mwzb.com

AJZ:kmo

Filed: 13 February 2002

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Claims 3-5, 8-11, 14-15 and 18 were amended as follows:

3. (Amended) An application according to claim 1 ~~or 2~~, wherein the virus infection is an infection caused by retrovirus, in particular lentivirus, for instance HIV.

4. (Amended) An application according to claim 1 ~~to 3~~, wherein the virus inhibitor is a reverse transcriptase inhibitor, preferably a pyrimidin nucleoside analogue, most preferably 3'-azido-3'-desoxythymidine (AZT or zidovudine), and as an option further other nucleoside analogues different therefrom, preferably 3TC, are included in the pharmaceutical composition.

5. (Amended) An application according to claim 1 ~~to 4~~, wherein the pharmaceutical composition further contains a protease inhibitor, and as an option further protease inhibitors different therefrom.

8. (Amended) A pharmaceutical composition according to claim 6 ~~or 7~~, wherein

the drug components drug component b) is a pyrimidin nucleoside analogue, preferably 3'-azido-3'-desoxythymidine, and/or

the drug component c) is 3TC, and/or

the drug component d) is provided in a conclusive manner.

9. (Amended) A pharmaceutical composition according to ~~one of claims 6 to 8~~, wherein the drug components b) to e) are part of a first package component, and the drug component a) is part of a second package component.

10. (Amended) A package component according to ~~one of claims 6 to 9~~, containing the drug component a).

11. (Amended) A method for treating virus infections with retrovirus, in particular lentivirus, for instance HIV, wherein the pharmaceutical composition according to ~~claims 6 to 9~~ is administered to a human body or to the body of a lower warm-blooded animal attacked by the infection.

14. (Amended) A method according to ~~claim 12 or 13~~, wherein the drug components b) to e) are administered continuously and the drug component a) once or several times in time intervals with breaks.

15. (Amended) A method according to ~~one of claims 12 to 14~~,  
wherein

——the drug component b) is a pyrimidin nucleoside analogue,  
preferably 3'-azido-3'-desoxythymidine, ~~and/or~~

——~~the~~and/or

the drug component c) is 3TC, and/or

——the drug component d) is provided in a conclusive manner.

18. (Amended) An application, pharmaceutical composition,  
package component or method according to ~~one of claims 1 to 17~~,  
wherein the monoclonal antibody is CMY-2, available from  
hybridom cells according to deposit DSM ACC2353, or the clone  
ANC28.1/5D10, or a preferably humanized or human-tolerated  
variant of the clone ANC28.1/ 5D10.